Kerecis ehf - Product Pipeline Analysis, 2023 Update

Summary

Kerecis ehf (Kerecis) operates as a medical device company that provides products that treat chronic wounds and damaged tissue. The company’s flagship product includes Kerecis Omega3 fish-skin acellular dermal matrix transplantation technology is intended for use in products to treat acute, chronic, and oral wounds, for dura mater repair, breast reconstruction, and abdominal wall reconstruction, and for surgical stapling. It also develops mOmega3 fatty acid (fish-sourced fatty acids) technology for use in several dermatological indications such as psoriasis, eczema, dermatitis, keratosis pilaris, and pseudofolliculitis. Kerecis also provides fish-skin acellular dermal matrix products including Omega3 Wound, Omega3 Dura, Omega3 Hernia, Omega3 Pectus, Omega3 Seal, and topical creams including Smooth with mOmega3, Footguard with mOmega3, Psoria with mOmega3 and Xma with mOmega3. The company uses complete acellular fish skin for tissue regeneration by transplantation. Kerecis is headquartered in Isafjordur, Iceland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

• The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
• The report analyzes all pipeline products in development for the company Kerecis ehf
• The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
• The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
• The report provides detailed description of products in development, technical specification and functions
• The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
• Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
• To formulate effective Research & Development strategies
• Develop market-entry and market expansion strategies
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
• Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note:Some sections may be missing if data is unavailable for the company